Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.
It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS or SPMS will also be communicated, the company said... Read More - http://www.ms-uk.org/index.cfm/gilenya
Novartis To Present New Data On Multiple Sclerosis Treatment
Novartis To Present New Data On Multiple Sclerosis Treatment
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1672 Views
-
Last post by frodo
-
- 1 Replies
- 1736 Views
-
Last post by frodo
-
- 0 Replies
- 1525 Views
-
Last post by frodo
-
- 0 Replies
- 1460 Views
-
Last post by frodo
-
- 0 Replies
- 1138 Views
-
Last post by frodo
-
- 0 Replies
- 3502 Views
-
Last post by frodo
-
- 0 Replies
- 2067 Views
-
Last post by frodo
-
- 0 Replies
- 1765 Views
-
Last post by NHE
-
- 0 Replies
- 747 Views
-
Last post by maggieMSOC